CHICAGO – "In cancer pharmacology," Memorial Sloan-Kettering Cancer Center's Charles Rudin told the audience at the annual meeting of the American Society of Clinical Oncology, "it's all about the therapeutic window" – the dose range at which a drug will kill tumor cells without poisoning the patient taking them.